{{ 'fb_in_app_browser_popup.desc' | translate }} {{ 'fb_in_app_browser_popup.copy_link' | translate }}
{{ 'in_app_browser_popup.desc' | translate }}
Suitable for 18 years old or above
Not enough stock.
Your item was not added to your cart.
Not enough stock.
Please adjust your quantity.
{{'products.quick_cart.out_of_number_hint'| translate}}
{{'product.preorder_limit.hint'| translate}}
Limit {{ product.max_order_quantity }} per order.
Only {{ quantityOfStock }} item(s) left.
【21-valentPneumococcal Conjugate Vaccine (PCV21)】1 dose (Suitable for 18 years old or above)
Adults aged 18 or above: 1 Dose
Product Description
【Next-Gen Vaccine Now Available! Lifetime Protection with Just 1 Dose】
The latest generation 21-valent pneumococcal conjugate vaccine (PCV21, CAPVAXIVE®) is developed by MSD (Merck & Co., Inc.) and specifically tailored for the prevention of invasive pneumococcal disease (IPD) in adults.
Featuring an all-new formulation, it precisely incorporates 8 new serotypes that predominantly affect adults, providing a more comprehensive and long-lasting barrier for your and your family's respiratory health.
🌟 3 Key Highlights of the Vaccine
🩺 Recommended Target Groups
This vaccine is approved for adults aged 18 or above, and is strongly recommended for the following high-risk groups:

If assessed as unfit for vaccination, a HKD $200 consultation fee applies, and the remaining amount will be refunded.
Payment confirms acceptance of the [Booking Process] and [Terms of Use]; failure to comply may result in service termination. Kinetics Medical & Health Group reserves all final decisions.